These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24637174)

  • 1. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults.
    Grabenstein JD; Musey LK
    Vaccine; 2014 May; 32(21):2399-405. PubMed ID: 24637174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
    Ciprero KL; Marchese RD; Richard P; Baudin M; Sterling TM; Manoff SB; Radley D; Stek JE; Soubeyrand B; Grabenstein JD; Samson SI; Musey LK
    Hum Vaccin Immunother; 2016 Aug; 12(8):2135-2141. PubMed ID: 27002793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
    Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
    Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Disribution of Streptococcus pneumoniae serotypes and serogroups among patients with invasive pneumococcal diseases in the Czech Republic in 1996-2003: background data for vaccination strategy].
    Motlová J
    Epidemiol Mikrobiol Imunol; 2005 Feb; 54(1):3-10. PubMed ID: 15807381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001.
    Leach AJ; Morris PS; McCallum GB; Wilson CA; Stubbs L; Beissbarth J; Jacups S; Hare K; Smith-Vaughan HC
    BMC Infect Dis; 2009 Aug; 9():121. PubMed ID: 19650933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype.
    Sá-Leão R; Pinto F; Aguiar S; Nunes S; Carriço JA; Frazão N; Gonçalves-Sousa N; Melo-Cristino J; de Lencastre H; Ramirez M
    J Clin Microbiol; 2011 Apr; 49(4):1369-75. PubMed ID: 21270219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
    J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13-valent pneumococcal conjugate vaccine (PCV13).
    Jefferies JM; Macdonald E; Faust SN; Clarke SC
    Hum Vaccin; 2011 Oct; 7(10):1012-8. PubMed ID: 21941097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from invasive infections after optional use of the 7-valent conjugate vaccine in Korea, 2006-2010.
    Cho EY; Lee H; Choi EH; Kim YJ; Eun BW; Cho YK; Kim YK; Jo DS; Lee HS; Lee J; Kim MN; Kim DS; Lee HJ
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):481-6. PubMed ID: 24529940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility profiles and correlation with pneumococcal serotypes soon after implementation of the 10-valent pneumococcal conjugate vaccine in Brazil.
    Mott M; Caierão J; Rosa da Cunha G; Rodrigues Perez LR; Matusiak R; Pilger de Oliveira KR; d'Azevedo PA; Dias C
    Int J Infect Dis; 2014 Mar; 20():47-51. PubMed ID: 24389158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study.
    Meichtry J; Born R; Küffer M; Zwahlen M; Albrich WC; Brugger SD; Mühlemann K; Hilty M
    Vaccine; 2014 Sep; 32(40):5185-91. PubMed ID: 25077419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 23-valent polysaccharide vaccine (PPSV23)-targeted serotype-specific identification of Streptococcus pneumoniae using the loop-mediated isothermal amplification (LAMP) method.
    Lee J; Yoon Y; Kim EJ; Lee D; Baek Y; Takano C; Chang B; Iijima T; Kilgore PE; Hayakawa S; Hoshino T; Kim DW; Seki M
    PLoS One; 2021; 16(2):e0246699. PubMed ID: 33591996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.
    Jansen AG; Rodenburg GD; van der Ende A; van Alphen L; Veenhoven RH; Spanjaard L; Sanders EA; Hak E
    Clin Infect Dis; 2009 Jul; 49(2):e23-9. PubMed ID: 19522653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.